Day One Bio (DAWN) - שווי פעילות לרווח לפני ריבית, מסים ופחת
The line of targeted therapies for children is entering a stage of commercial growth, ensuring a protected patent cycle. Reviewing the EV/EBITDA multiple for Day One (DAWN) over time on GURU.Markets, we see that the 0.00 metric confirms the current valuation level. This is further supported by the high authority of Day One in treating brain tumors, while the orphan drug status of its products guarantees a monopoly position and stable revenue.
DAWN (dayonebio.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים
The EV/EBITDA multiple compares the total enterprise value, including debt, with operating profit, allowing for an assessment of capital management efficiency and debt load. The current value of 0.00 and the fluctuations in the EV/EBITDA level of Day One (DAWN) demonstrate the stability of grant-based financing, which is critical for Day One as it scales distribution and brings its pediatric oncology drug to market.
